Pharmaceuticals

Prostate Cancer Therapeutics Market Performance and Future Outlook at 8.4% CAGR Through 2029

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prostate cancer therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Prostate Cancer Therapeutics Industry By 2029?

The prostate cancer therapeutics market has shown robust expansion in recent years. Its valuation is set to increase from $11.92 billion in 2024 to $12.88 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to the rising global occurrence of prostate cancer, heightened understanding of early cancer screening and diagnostic initiatives, an expanding elderly male population, and a growing call for tailored and specific therapies.

The prostate cancer therapeutics market is anticipated to experience robust expansion over the next few years, with its size projected to reach $17.77 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.4%. This anticipated growth is primarily driven by factors such as increased healthcare expenditure in emerging economies, a surge in investments directed towards oncology drugs, the expanding availability of advanced imaging and diagnostic tools, and a growing adoption of minimally invasive and non-surgical treatment options. Significant trends expected during this period include further advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, ongoing progress in radioligand-based treatments, and continued innovations in immunotherapy for prostate cancer.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Impacting The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is projected to stimulate the expansion of the prostate cancer therapeutics market in the coming years. Prostate cancer is characterized by the development of malignant cells within the prostate gland’s tissues, primarily impacting elderly males. The growth in prostate cancer cases can be attributed to an aging global demographic, as the likelihood of developing this condition substantially increases with age, and extended life expectancies mean more men reach an age where they are susceptible. Prostate cancer treatments are crucial for managing the illness by targeting cancerous cells, impeding disease progression, and enhancing patients’ quality of life through various interventions, including surgical procedures, radiation therapy, hormonal treatments, and advanced therapies like immunotherapy. For example, data released in October 2024 by the National Health Service, a UK-based government department, indicated that male cancer diagnoses saw an overall increase of 7% in 2022, climbing from 167,917 to 180,877 instances. This particular increase was predominantly fueled by a considerable spike in prostate cancer diagnoses, which surged by over 25% to 54,732 cases. Consequently, the escalating incidence of prostate cancer is a primary driver for the advancement of the prostate cancer therapeutics market.

Which Segment Categories Are Driving Maximum Growth In The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine-Based Therapies

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy, Tyrosine Kinase Inhibitors

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Which Long-Term Trends Will Play A Crucial Role In The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient adherence and overall treatment effectiveness. This daily oral pill for advanced prostate cancer refers to therapies administered once a day to manage metastatic castration-resistant prostate cancer by hindering testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, which is India’s initial daily oral pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies quickly suppresses testosterone, aiding in controlling cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the requirement for injectable treatments that necessitate administration by healthcare professionals, thereby providing greater patient convenience. This introduction signifies a major stride in prostate cancer management in India, offering patients and doctors a new, accessible, secure, and cost-effective treatment alternative.

Who Are The Dominant Players In The Prostate Cancer Therapeutics Market Today?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Is At The Forefront Of Innovation In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2025, By The Business Research Company

Prostate Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Thyroid Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795